WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System

  WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System

Business Wire

SAN DIEGO & SHANGHAI -- March 10, 2014

Illumina, Inc. (NASDAQ:ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a
leading pharmaceutical, biotechnology, and medical device R&D outsourcing
company with operations in China and the United States, today announced that
the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing

This new investment will enable WuXi’s clinical genomic services to expand
from the current target panel, exome, and transcriptome scale sequencing to
population genome scale sequencing. It puts the world’s most advanced gene
sequencing capability in the hands of the leading pharmaceutical R&D services
company in the Asia Pacific region.

The WuXi Genome Center meets international clinical standards and is the only
CLIA-certified clinical genomics lab in China. In addition to offering
sequencing services, WuXi’s genomics lab also provides assay development,
validation, and testing services.

“This investment in cutting-edge gene sequencing technology significantly
strengthens WuXi’s broad, integrated platform of R&D services,” said Dr. Ge
Li, Chairman and CEO of WuXi PharmaTech. “It advances our mission of enabling
anyone and any company to use our R&D platform to discover and develop
innovative medicines to benefit the world’s patients.”

The HiSeq X Ten is the world’s first platform to deliver full coverage human
genomes for $1,000, including typical instrument depreciation, DNA extraction,
library preparation, and estimated labor. Purpose-built for population-scale
human whole genome sequencing, the HiSeq X Ten can sequence approximately
18,000 samples annually with high-quality, high-coverage sequencing. It is
sold as a set of 10 or more ultra-high throughput sequencing systems, each
generating up to 1.8 terabases (Tb) of sequencing data in less than three days
or up to 600 gigabases (Gb) per day, per system.

“We are pleased that WuXi has chosen the HiSeq X Ten to serve its clients with
state-of-the-art gene sequencing capabilities,” said Jay Flatley, CEO of
Illumina. “Illumina’s leadership in the development of genomics technologies
and WuXi’s leadership in offering high-quality R&D services to leading
biopharmaceutical companies are a perfect fit.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statement for Illumina

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with theSecurities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this

About WuXi PharmaTech

WuXi PharmaTech (www.wuxiapptec.com) is a leading pharmaceutical,
biotechnology, and medical device R&D outsourcing company, with operations in
China and the United States. As a research-driven and customer-focused
company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical
device companies with a broad and integrated portfolio of laboratory and
manufacturing services throughout the drug and medical device R&D process.
WuXi PharmaTech's services are designed to help its global partners in
shortening the cycle and lowering the cost of drug and medical device R&D. The
operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.


Rebecca Chambers, 858-255-5243
Jennifer Temple, 858-882-6822
WuXi PharmaTech
Ronald Aldridge, 201-585-2048
Aaron Shi, +86-21-5046-4362
Press spacebar to pause and continue. Press esc to stop.